Update results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.

被引：0
|
作者：
Chang, Zhiwei [1 ]
Liu, Xiao-Lei [1 ]
Yu, Dan-Dan [1 ]
Han, Hui-Qiong [1 ]
He, Jian [1 ]
Wang, Rui-Rui [1 ]
Jia, Yong-Xu [1 ]
Yan, Jie [1 ]
Qin, Yanru [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Med Oncol, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16017
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Centchroman as First-line Treatment for Mastalgia: Results of an Open-label, Single-arm Trial
    Rathi, Jalaj
    Chawla, Inderjit
    Singh, Karnail
    Chawla, Arjun
    BREAST JOURNAL, 2016, 22 (04): : 407 - 412
  • [32] Fruquinitinib combined with nab-paclitaxel and gemcitabine (AG) as the first-line treatment for pancreatic ductal adenocarcinoma (PDAC) with liver metastases: An open-label, single-arm, single-center phase II clinical study
    Wei, M.
    Shi, S.
    Li, J.
    Du, N.
    Yu, X.
    Xu, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S933 - S933
  • [33] A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma
    Li, Ning
    Wu, Tao
    Hong, Yong-Gui
    Guo, Yan-Zhen
    Cheng, Yu-Feng
    Ma, Yi-Jie
    Bie, Liang-Yu
    Cui, Dong-Hai
    Gao, Xiao-Hui
    Tan, Bing-Xu
    Li, Bao-Sheng
    Luo, Su-Xia
    Wang, Jun-Sheng
    BMC MEDICINE, 2022, 20 (01)
  • [34] A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma
    Ning Li
    Tao Wu
    Yong-Gui Hong
    Yan-Zhen Guo
    Yu-Feng Cheng
    Yi-Jie Ma
    Liang-Yu Bie
    Dong-Hai Cui
    Xiao-Hui Gao
    Bing-Xu Tan
    Bao-Sheng Li
    Su-Xia Luo
    Jun-Sheng Wang
    BMC Medicine, 20
  • [35] Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial
    Xu, Ling-Xiao
    Yuan, Jia-Jia
    Xue, Ran
    Zhou, Jun
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (30)
  • [36] Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study
    Wang Feng
    Wang Junsheng
    Wu Tao
    Hong Yonggui
    Meng Xiangrui
    Ren Zhonghai
    Guo Yanzhen
    Yang Xiuli
    Shi Pei
    Yang Jiamei
    Fan Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [37] Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial
    Gong, Lei
    Yang, Yueyang
    Zhang, Hongdian
    Qiao, Yufeng
    Wang, Haitong
    Ren, Peng
    Tang, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer: A multicenter, single-arm, phase I/II trial
    Pressiani, T.
    Balsano, R.
    Giordano, L.
    Milella, M.
    Bergamo, F.
    Bozzarelli, S.
    Noventa, S.
    Ferrari, D.
    Scartozzi, M.
    Parra, H. J. Soto
    Auriemma, A.
    Solda, C.
    Zaniboni, A.
    Zecchetto, C.
    Rizzato, M. D.
    Rimassa, L.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S120 - S120
  • [39] Neoadjuvant chemoradiotherapy (nCRT) combined with sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): Preliminary results of a single-arm, open-label phase Ib trial (CRIS)
    Jiang, Youhua
    Qiu, Guoqin
    Li, Jianqiang
    Wang, Jiangfeng
    Wang, Changchun
    Wu, Jie
    Cheng, Lei
    Zheng, Yuanda
    Ruan, Rongwei
    Song, Ge
    Ye, Xuemei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.
    Wei, Wei
    Ban, Xiaohua
    Yang, Fan
    Huang, Yongwen
    Li, Jibin
    Qiu, Ya
    Cheng, Xiaqin
    Li, Jundong
    Zheng, Min
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345